Atlas Genetics Ready To Play Its Part In The POC Workflow Revolution

Do it once, do it right and do it quick: when it comes to diagnostic testing, that suits patients and payer systems that are pursuing budget-sensitive, quality-driven health care solutions. It could also be the shorthand mission statement of POC diagnostics developer Atlas Genetics, which is developing a new IVD platform technology for infectious disease tests.

IV1611_Atlas_1200x675

UK company Atlas Genetics Ltd. was founded in 2005 as a spin-out from Osmetech PLC and the University of Bath to exploit the point of care (POC) market for infectious diseases. When John Clarkson, PhD, joined US-based and UK-listed Osmetech as incoming CEO of the unit that became Atlas Genetics Ltd. he recognized that the company was under-utilizing some of its IP assets and saw both the opportunity – and the challenges – of developing its infectious disease diagnostic chemistry.

Clarkson had to strike the right balance of investment: it had to remain modest until the company had developed a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By 

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.